[go: up one dir, main page]

WO2005056766A3 - TARGETED DRUG DELIVERY USING EphA2 OR Eph4 BINDING MOIETIES - Google Patents

TARGETED DRUG DELIVERY USING EphA2 OR Eph4 BINDING MOIETIES Download PDF

Info

Publication number
WO2005056766A3
WO2005056766A3 PCT/US2004/041020 US2004041020W WO2005056766A3 WO 2005056766 A3 WO2005056766 A3 WO 2005056766A3 US 2004041020 W US2004041020 W US 2004041020W WO 2005056766 A3 WO2005056766 A3 WO 2005056766A3
Authority
WO
WIPO (PCT)
Prior art keywords
epha2
therapeutic
composition
hyperproliferative
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2004/041020
Other languages
French (fr)
Other versions
WO2005056766A2 (en
Inventor
Michael S Kinch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune LLC
Original Assignee
MedImmune LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/004,794 external-priority patent/US20050153923A1/en
Priority claimed from US11/004,795 external-priority patent/US20050147593A1/en
Application filed by MedImmune LLC filed Critical MedImmune LLC
Publication of WO2005056766A2 publication Critical patent/WO2005056766A2/en
Anticipated expiration legal-status Critical
Publication of WO2005056766A3 publication Critical patent/WO2005056766A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention relates to methods and compositions designed for the treatment, management, or prevention of a hyperproliferative cell disease, particularly cancer. The methods of the invention comprise the administration of an effective amount of a composition that targets cells expressing an Eph family receptor tyrosine kinase, such as EphA2 or EphA4, for the treatment, management, or prevention of hyperproliferative diseases, particularly cancer. In one embodiment, the method of the invention comprises administering to a subject a composition comprising an EphA2 or EphA4 targeting moiety attached to a delivery vehicle, and one or more therapeutic or prophylactic agents that treat or prevent a hyperproliferative disease, where the therapeutic or prophylactic agents that treat or prevent a hyperproliferative disease, where the therapeutic or prophylactic agents are operatively associated with the delivery vehicle. In another embodiment, the method of the invention comprises administering to a subject a composition comprising a nucleic acid comprising a nucleotide sequence encoding an EphA2 or EohA4 targeting moiety and a therapeutic or prophylactic agent that treats or prevents a hyperproliferative disease. In yet another embodiment, the method of the invention comprises administering to a subject a composition comprising an EphA2 or EphA4 targeting moiety and a nucleic acid comprising a nucleotide sequence encoding an agent that treats or prevents a hyperproliferative disease, where the nucleic acid is operatively associated with the delivery vehicle. Pharmaceutical compositions are also provided by the present invention.
PCT/US2004/041020 2003-12-04 2004-12-06 TARGETED DRUG DELIVERY USING EphA2 OR Eph4 BINDING MOIETIES Ceased WO2005056766A2 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US52739603P 2003-12-04 2003-12-04
US60/527,396 2003-12-04
US11/004,794 2004-12-03
US11/004,794 US20050153923A1 (en) 2003-12-04 2004-12-03 Targeted drug delivery using EphA2 or EphA4 binding moieties
US11/004,795 2004-12-03
US11/004,795 US20050147593A1 (en) 2003-05-22 2004-12-03 EphA2, EphA4 and LMW-PTP and methods of treatment of hyperproliferative cell disorders

Publications (2)

Publication Number Publication Date
WO2005056766A2 WO2005056766A2 (en) 2005-06-23
WO2005056766A3 true WO2005056766A3 (en) 2008-01-31

Family

ID=34682013

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/041020 Ceased WO2005056766A2 (en) 2003-12-04 2004-12-06 TARGETED DRUG DELIVERY USING EphA2 OR Eph4 BINDING MOIETIES

Country Status (1)

Country Link
WO (1) WO2005056766A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776327B2 (en) 1999-08-17 2010-08-17 Purdue Research Foundation EphA2 as a therapeutic target for cancer

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006501153A (en) 2002-05-23 2006-01-12 パーデュー・リサーチ・ファウンデーション Low molecular weight protein tyrosine phosphatase (LMW-PTP) as a diagnostic and therapeutic target
EP1618184A4 (en) * 2003-04-11 2006-06-21 Medimmune Inc Epha2, hypoproliferative cell disorders and epithelial and endothelial reconstitution
US20050059592A1 (en) * 2003-04-11 2005-03-17 Kiener Peter A. EphA2 and hyperproliferative cell disorders
WO2005048917A2 (en) * 2003-06-06 2005-06-02 Medimmune, Inc. Use of epha4 and modulator or epha4 for diagnosis, treatment and prevention of cancer
EP1689346A4 (en) * 2003-11-20 2007-11-21 Medimmune Inc EPHA2 AGONISTIC MONOCLONAL ANTIBODIES AND METHODS OF USING SAME
WO2006026820A1 (en) * 2004-09-08 2006-03-16 The University Of Queensland Treating gliosis, glial scarring, inflammation or inhibition of axonal growth in the nervous system by modulating eph receptor
EP2946786A1 (en) * 2006-03-08 2015-11-25 Wake Forest University Health Sciences Soluble monomeric Ephrin A1
EP1914242A1 (en) * 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
CA2680589A1 (en) * 2007-03-14 2008-09-18 Universita' Degli Studi Di Milano - Bicocca Modulator compounds of the drug resistance in epithelial tumour cells
PL2199390T3 (en) 2007-08-30 2017-06-30 Daiichi Sankyo Company, Limited Anti-epha2 antibody
KR20130056855A (en) 2010-03-01 2013-05-30 카리스 라이프 사이언스 룩셈부르크 홀딩스 Biomarkers for theranostics
WO2011127219A1 (en) 2010-04-06 2011-10-13 Caris Life Sciences Luxembourg Holdings Circulating biomarkers for disease

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040028685A1 (en) * 2002-05-10 2004-02-12 Kinch Michael S. EphA2 monoclonal antibodies and methods of use thereof
US20040180823A1 (en) * 2002-09-24 2004-09-16 Pasquale Elena B. Novel agents that modulate Eph receptor activity
US6927203B1 (en) * 1999-08-17 2005-08-09 Purdue Research Foundation Treatment of metastatic disease

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6927203B1 (en) * 1999-08-17 2005-08-09 Purdue Research Foundation Treatment of metastatic disease
US20040028685A1 (en) * 2002-05-10 2004-02-12 Kinch Michael S. EphA2 monoclonal antibodies and methods of use thereof
US20040180823A1 (en) * 2002-09-24 2004-09-16 Pasquale Elena B. Novel agents that modulate Eph receptor activity

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
BRANTLEY ET AL.: "Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo", ONCOGENE, vol. 21, 2002, pages 7011 - 7026 *
CARLES-KINCH ET AL.: "Antibody targeting of the EphA2 tyrosine kinase inhibits malignant cell behavior", CANCER RESEARCH, vol. 62, May 2002 (2002-05-01), pages 2840 - 2847 *
CHENG ET AL.: "Inhibition of VEGF-dependent multistage carcinogenesis by soluble EphA receptors", NEOPLASIA, vol. 5, no. 5, 2003, pages 445 - 456 *
CHENG ET AL.: "The Ephrins and Eph receptors in angiogenesis", CYTOKINE & GROWTH FACTOR REVIEWS, vol. 13, 2002, pages 75 - 85 *
CROSASSO ET AL.: "Antitumoral activity of liposomes and immunoliposomes containing 5-fluorouridine prodrugs", J. OF PHARMACEUTICAL SCIENCES, vol. 86, no. 7, July 1997 (1997-07-01), pages 832 - 839 *
EASTY ET AL.: "Loss of expression of receptor tyrosine kinase family genes PTK7 and SEK in metastatic melanoma", INT. J. CANCER, vol. 71, 1997, pages 1061 - 1065 *
KOOLPE ET AL.: "An ephrin mimetic peptide that selectively targets the EphA2 receptor", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 277, no. 49, 2002, pages 46974 - 46979 *
MERIC ET AL.: "Expression profile of tyrosine kinases in breast cancer", CLINICAL CANCER RESEARCH, vol. 8, 2002, pages 361 - 367 *
OGAWA ET AL.: "The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumor neovascularization", ONCOGENE, vol. 19, 2000, pages 6043 - 6052 *
ZELINSKI ET AL.: "EphA2 overexpression causes tumorigenesis of mammary epithelial cells", CANCER RESEARCH, vol. 61, 2001, pages 2301 - 2306 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776327B2 (en) 1999-08-17 2010-08-17 Purdue Research Foundation EphA2 as a therapeutic target for cancer
US8591887B2 (en) 1999-08-17 2013-11-26 Purdue Research Foundation EPHA2 as a therapeutic target for cancer

Also Published As

Publication number Publication date
WO2005056766A2 (en) 2005-06-23

Similar Documents

Publication Publication Date Title
WO2005055948A3 (en) Epha2, epha4 and lmw-ptp and methods of treatment of hyperproliferative cell disorders
WO2004111192A3 (en) Targeted delivery to legumain-expressing cells
WO2004105782A3 (en) Drug delivery systems for tumor targeting ngr-molecules and uses thereof
WO2006113623A3 (en) Elimination of heterogeneous or mixed cell population in tumors
US9080173B2 (en) Methods and compositions for RNAi-based cancer treatment
WO2005051429A3 (en) Targeted conjugates with a modified saccharide linker
WO2005056766A3 (en) TARGETED DRUG DELIVERY USING EphA2 OR Eph4 BINDING MOIETIES
WO2008036682A3 (en) Treatment of liver disorders by administration of receptor-associated protein (rap)-conjugates
WO2007143315A3 (en) Compounds and methods for modulating expression of pcsk9
MX2007009960A (en) Combinations and modes of administration of therapeutic agents and combination therapy.
WO2008039218A3 (en) Inhibitors of bruton's tyrosine kinase
WO2006039704A3 (en) Pharmaceutical composition and method for treating a joint capsule arthropathy
WO2005051297A3 (en) Combination drug therapy to treat obesity
WO2008097927A3 (en) Treatment and prevention of neurodegenerative diseases using gene therapy
WO2008109432A3 (en) Therapeutic targeting of interleukins using sirna in neutral liposomes
WO2007059342A3 (en) Random copolymer compositions for treating unwanted immune response
WO2004043378A3 (en) Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
WO2007078443A3 (en) Methods of treating unwanted immune response with random copolymers
WO2005009394A3 (en) Drug delivery in the nervous system
NO20061319L (en) 5-arylpyrimidines as anticancer drugs
WO2005115360A3 (en) Formulations of anti-pain agents and methods of using the same
WO2005094899A8 (en) Clusterin antisense therapy for treatment of cancer
TW200512211A (en) 6-[(substituted)phenyl]triazolopyrimidines as anticancer agents
WO2005120542A3 (en) Methods of treating disease with random copolymers
PL1732926T3 (en) Mitotic kinesin inhibitors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase